Adcentrx Therapeutics to showcase Preclinical findings of Nectin-4 ADC Program at AACR Annual Meeting 2024

CAR-T Digest - August 2020

1 Apr 2024: Adcentrx Therapeutics to showcase Preclinical findings of Nectin-4 ADC Program at AACR Annual Meeting 2024

Adcentrx Therapeutics will present preclinical data for ADRX-0706 at AACR Annual Meeting 2024
ADRX-0706 is Adcentrx’s lead ADC program, targeting human Nectin-4 with a novel tubulin inhibitor payload
The ADC utilizes Adcentrx’s i-conjugation technology, resulting in highly stable ADCs with a drug-antibody ratio of eight (DAR 8)
Preclinical data shows an improved therapeutic window, enhanced bystander effect, and optimized payload delivery to Nectin-4-expressing tumors while minimizing exposure to normal tissues
ADRX-0706 demonstrates favorable pharmacokinetics and safety profile in preclinical models, with significant efficacy across various tumor indications in vitro and in vivo
ADRX-0706 is currently being evaluated in a Phase 1a/b clinical trial (Study ID NCT06036121)